UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000036275
Receipt number R000041316
Scientific Title Protective and ameliorative effects of the extracts of Cistanche tubulosa on locomotive syndrome.
Date of disclosure of the study information 2019/04/01
Last modified on 2020/03/12 10:41:30

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Protective and ameliorative effects of the extracts of Cistanche tubulosa on locomotive syndrome.

Acronym

Protective and ameliorative effects of the extracts of Cistanche tubulosa on locomotive syndrome.

Scientific Title

Protective and ameliorative effects of the extracts of Cistanche tubulosa on locomotive syndrome.

Scientific Title:Acronym

Protective and ameliorative effects of the extracts of Cistanche tubulosa on locomotive syndrome.

Region

Japan


Condition

Condition

Subjects having the risk of locomotive syndrome

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

This study aims to investigate effects of the extract of Cistanche tubulosa on locomotive syndrome.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Function of locomotive systems

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

Numbered container method


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Food

Interventions/Control_1

Tretament test drug: Intake of powder containing the extracts of Cistanche tubulosa (1800 mg/bag), one bag per day, for 12 weeks.

Interventions/Control_2

Treatment placebo:Intake of powder without the extract, one bag per day, for 12 weeks.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

40 years-old <=

Age-upper limit

80 years-old >=

Gender

Male and Female

Key inclusion criteria

Subjects who checked at least one item among "Loco check" between age 40 to 80 years old, who volunteers to attend this clinical study.

Key exclusion criteria

Subjects under 20 years old, pregnant or lactating. Subjects during medication such as muscle relaxants, osteoporosis drugs, rheumatoid arthritis drugs.
Subjects having mental illnesses. Subjects judged being inappropriate by other reasons.

Target sample size

20


Research contact person

Name of lead principal investigator

1st name Chihiro
Middle name
Last name Tohda

Organization

University of Toyama

Division name

Division of Neuromedical Science, Institute of Natural Medicine

Zip code

930-0194

Address

2630 Sugitani, Toyama, 930-0194, JAPAN

TEL

076-434-7646

Email

chihiro@inm.u-toyama.ac.jp


Public contact

Name of contact person

1st name Chihiro
Middle name
Last name Tohda

Organization

University of Toyama

Division name

Division of Neuromedical Science, Institute of Natural Medicine

Zip code

930-0194

Address

2630 Sugitani, Toyama, 930-0194, JAPAN

TEL

076-434-7646

Homepage URL


Email

chihiro@inm.u-toyama.ac.jp


Sponsor or person

Institute

Division of Neuromedical Science, Institute of Natural Medicine, University of Toyama

Institute

Department

Personal name



Funding Source

Organization

MEXT

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

IRB center, Sugitani campus, University of Toyama

Address

2630 Sugitani, Toyama, 930-0194, JAPAN

Tel

076-434-7145

Email

yuka@adm.u-toyama.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

国立大学法人 富山大学


Other administrative information

Date of disclosure of the study information

2019 Year 04 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

20

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2018 Year 11 Month 02 Day

Date of IRB

2018 Year 11 Month 26 Day

Anticipated trial start date

2019 Year 05 Month 11 Day

Last follow-up date

2019 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2019 Year 03 Month 22 Day

Last modified on

2020 Year 03 Month 12 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000041316


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name